No Products in the Cart

The information in this article is intended for general educational purposes only and should not replace professional medical advice. If you have questions about diabetes management or treatment options, speak with your doctor or diabetes healthcare team for guidance based on your individual needs.
Senseonics has started human testing of Freedom, a next-generation continuous glucose monitor designed to measure glucose for up to a year without requiring an external transmitter. Here's how it works and what this development could mean for the future of glucose monitoring.
Continuous glucose monitors (CGMs) have changed the way many people manage diabetes. Instead of relying solely on finger-prick tests, people can see their glucose levels throughout the day, follow trends and receive alerts when their levels are too high or too low.
But what if a CGM didn't require a sensor attached to the skin or a separate transmitter?
That's the idea behind Freedom, an experimental implantable CGM being developed by medical technology company Senseonics. In October 2026, the company announced that it had started its first human clinical study, marking an important step towards a new generation of glucose monitoring technology.
Let's look at how it works, how it differs from current CGMs and what we know so far.
Freedom is a next-generation continuous glucose monitor designed to sit entirely underneath the skin, with no external transmitter needed.
The technology builds on Senseonics' existing Eversense 365 system, which already uses a small sensor implanted under the skin of the upper arm.
The main difference is how the new device communicates. With current Eversense technology, an external transmitter sits over the implanted sensor. It collects information from the sensor and sends glucose readings to a compatible smartphone.
Freedom is being developed with two additional features built into the implanted sensor:
An integrated battery: This would provide power to the implanted device.
Bluetooth communication: This would allow the sensor to send glucose readings directly to a smartphone.
In simple terms, the aim is to remove the need for a separate device worn on the skin while keeping continuous glucose readings available through a smartphone app.
The proposed sensor is designed to last for up to 12 months.
You might be wondering how a device placed underneath the skin can measure glucose levels.
Unlike traditional blood glucose meters, CGMs measure glucose in the interstitial fluid. This is the fluid that surrounds the body's cells and sits just beneath the skin.
An implantable CGM works in a similar way to other CGM systems, but its sensor is placed under the skin by a healthcare professional rather than being attached to the surface.
Here's how the technology works:
Sensor insertion: A healthcare professional places a small sensor underneath the skin, usually in the upper arm.
Glucose measurement: The sensor continuously measures glucose levels in the surrounding interstitial fluid.
Data transmission: The sensor communicates the glucose information to another device.
Smartphone readings: The information is displayed in a compatible app, allowing users to follow their glucose levels and trends.
With Freedom, the goal is for the implanted sensor to handle both the measurement and wireless communication, removing the external transmitter used by the current Eversense system.
Most CGMs available today use a small sensor attached to the skin. Depending on the device, this sensor may need replacing every 7 to 14 days.
Senseonics has taken a different approach with its Eversense technology. Instead of replacing an externally attached sensor regularly, the sensor is inserted underneath the skin and designed to remain in place for up to one year.
However, Eversense 365 still requires an external transmitter that sits over the implanted sensor. This transmitter needs charging and is attached to the skin using an adhesive patch. Freedom aims to remove that additional hardware.
Here's a simple comparison:
| Feature | Eversense 365 | Freedom |
|---|---|---|
| Sensor location | Under the skin | Under the skin |
| Sensor duration | Up to 365 days | Designed for up to 365 days |
| External transmitter | Required | Not required |
| Battery | In external transmitter | Designed to be integrated into sensor |
| Smartphone connection | Via transmitter | Direct Bluetooth connection |
| Development status | Available in selected markets | Early human testing |
Note: The key difference is that Freedom is being designed to communicate directly with a smartphone without a separate transmitter.
Freedom isn't the only next-generation implantable CGM being developed by Senseonics. The company is also working on another system called Gemini.
While both technologies aim to give people more flexibility, they work differently.
Gemini: Two ways to access glucose readings
Gemini is being developed to offer two monitoring options:
Scan-only mode: Users could scan the implanted sensor with a compatible smartphone to retrieve stored glucose readings, without wearing the external transmitter. The proposed system can store up to eight hours of readings.
Continuous monitoring mode: Users could wear an external transmitter to receive ongoing glucose readings and alerts.
Freedom takes this concept further by aiming to provide continuous glucose monitoring without requiring a separate transmitter. This could be particularly interesting for people who want automatic glucose readings without wearing additional hardware on their skin.
Both systems are still subject to development and regulatory milestones.
On 26 October 2026, Senseonics announced that it had started the first human clinical study of Freedom.
Before this stage, the company tested different Bluetooth antenna designs and potential sensor implantation positions.
According to Senseonics, its preferred design achieved 100% communication success within its target distance during approximately seven weeks of preclinical testing, with more than 18,500 communication data points collected.
These results helped the company select a preferred design to take into human testing.
It's an encouraging development, but there is an important distinction: these communication results came from preclinical testing. They do not demonstrate that Freedom has achieved the same performance in people.
The first human study is an early feasibility study. Its purpose is to assess the device's safety and functionality, including whether the implanted sensor can communicate directly with a smartphone.
Senseonics has outlined the following development timeline:
2026: First human clinical study begins.
2027: Planned start of a larger pivotal clinical study.
2028: Potential commercial launch, depending on clinical results and regulatory approval.
These are the company's current development targets, not confirmed dates for availability.
If successful, Freedom could introduce another option for people who use continuous glucose monitoring. Removing the external transmitter could offer several potential benefits:
Less equipment to wear
Without a separate transmitter attached to the skin, users could have fewer components to manage as part of their daily routine.
Fewer adhesive-related considerations
The current Eversense system uses an adhesive patch to hold its external transmitter in place. Removing the transmitter could reduce the need for this particular adhesive, although other skin and insertion-related considerations would remain.
Continuous readings without an external transmitter
The proposed Bluetooth technology would allow the implanted sensor to communicate directly with a smartphone, meaning users wouldn't need to wear an additional transmitter to receive readings.
Longer sensor duration
The planned one-year sensor life could mean fewer sensor replacement procedures compared with CGMs that require regular external sensor changes.
Of course, these are potential advantages based on the device's intended design. More clinical research is needed to understand how well the system works and what the experience will be like for users.
Senseonics is currently targeting a potential commercial launch in 2028.
However, Freedom is still an investigational medical device. It needs to progress through clinical testing and meet regulatory requirements before it can become commercially available.
There is also no confirmed information about when or whether it will become available in Australia.
For now, it is best viewed as an interesting development in the future of glucose monitoring rather than a product people can access today.
CGM technology continues to develop, with companies exploring ways to make glucose monitoring more convenient and better suited to different lifestyles.
From longer-lasting sensors to improved connectivity and implantable technology, these developments are creating more possibilities for people managing diabetes.
Senseonics Freedom is an interesting step in that direction. If successful, it could offer a different approach to continuous glucose monitoring by removing the need for an external transmitter altogether.
We'll be keeping an eye on the clinical progress and future updates as more information becomes available.
What do you think about an implantable CGM that sends readings directly to your smartphone without an external transmitter? Would this be something you'd consider?
Senseonics official announcement, 26 October 2026. The primary source for the Freedom study and development timeline.
FDA technical documentation for Eversense 365. Explains how the sensor measures glucose and communicates with the transmitter.
Senseonics SEC filing. Additional information about the Gemini and Freedom development programmes.FUTURE
Freedom is an investigational implantable continuous glucose monitor being developed by Senseonics. It is designed to measure glucose levels from a sensor placed underneath the skin and send readings directly to a smartphone without requiring an external transmitter.
Freedom is being developed with a target sensor life of up to 365 days (one year). This is a proposed feature and will need to be evaluated through clinical testing.
Both systems use an implantable sensor designed to last up to one year. However, Eversense 365 requires an external transmitter worn over the sensor to send glucose readings to a smartphone. Freedom is designed to include an integrated battery and Bluetooth communication, removing the need for this external transmitter.
Senseonics is targeting a potential commercial launch in 2028. The device is currently undergoing early human clinical testing, with a larger pivotal study planned for 2027. Availability will depend on clinical results and regulatory approval.
No. Freedom is still an investigational device and is not currently commercially available in Australia. There is no confirmed Australian release date. Further clinical studies and regulatory approval will be required before it can be offered to consumers.
Explore our blog for more tips and resources on diabetes management.
Disclaimer: This blog is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your doctor or a qualified health provider with any questions about your condition. If you have a medical emergency, call 911 (US) or 000 (Australia) immediately, or visit your nearest emergency care center.

Discover more about our products and solutions to enhance your diabetes management journey. Join our community and experience the difference with Glucology today!